• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

Ritonavir-Boosted Protease Inhibitors Do Not Significantly Affect the Performance of Creatinine-Based Estimates of GFR.

作者信息

Wyatt Christina M, Chaudhari Juhi, Miao Shiyuan, Krishnasami Zipporah, Hellinger James, Levey Andrew S, Ross Michael, Ryom Lene, Mocroft Amanda, Brunet Laurence, Fusco Jennifer, Inker Lesley A

机构信息

Department of Medicine and Nephrology, Duke University School of Medicine, Durham, North Carolina, USA.

Department of Medicine and Nephrology, Tufts Medical Center, Boston, Massachusetts, USA.

出版信息

Kidney Int Rep. 2020 Feb 5;5(5):734-737. doi: 10.1016/j.ekir.2020.01.020. eCollection 2020 May.

DOI:10.1016/j.ekir.2020.01.020
PMID:32405595
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC7210603/
Abstract
摘要
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/5378/7210603/455b64f6f63b/gr1.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/5378/7210603/455b64f6f63b/gr1.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/5378/7210603/455b64f6f63b/gr1.jpg

相似文献

1
Ritonavir-Boosted Protease Inhibitors Do Not Significantly Affect the Performance of Creatinine-Based Estimates of GFR.利托那韦增强型蛋白酶抑制剂对基于肌酐的肾小球滤过率估算值的表现无显著影响。
Kidney Int Rep. 2020 Feb 5;5(5):734-737. doi: 10.1016/j.ekir.2020.01.020. eCollection 2020 May.
2
Substitution of raltegravir for ritonavir-boosted protease inhibitors in HIV-infected patients: the SPIRAL study.拉替拉韦替代利托那韦增效的蛋白酶抑制剂治疗 HIV 感染患者：SPIRAL 研究。
AIDS. 2010 Jul 17;24(11):1697-707. doi: 10.1097/QAD.0b013e32833a608a.
3
Cardiovascular disease and use of contemporary protease inhibitors: the D:A:D international prospective multicohort study.心血管疾病与当代蛋白酶抑制剂的使用：D:A:D 国际前瞻性多队列研究。
Lancet HIV. 2018 Jun;5(6):e291-e300. doi: 10.1016/S2352-3018(18)30043-2. Epub 2018 May 3.
4
Pharmacological and therapeutic properties of ritonavir-boosted protease inhibitor therapy in HIV-infected patients.利托那韦增强型蛋白酶抑制剂疗法在HIV感染患者中的药理及治疗特性
J Antimicrob Chemother. 2004 Jan;53(1):4-9. doi: 10.1093/jac/dkh029. Epub 2003 Dec 4.
5
Low-dose versus standard-dose ritonavir-boosted atazanavir in virologically suppressed Thai adults with HIV (LASA): a randomised, open-label, non-inferiority trial.低剂量与标准剂量利托那韦增强的阿扎那韦在病毒学抑制的泰国 HIV 成人中的比较（LASA）：一项随机、开放标签、非劣效性试验。
Lancet HIV. 2016 Aug;3(8):e343-e350. doi: 10.1016/S2352-3018(16)30010-8. Epub 2016 May 24.
6
Superior virological efficacy of ritonavir-boosted protease inhibitor regimens compared to single protease inhibitor therapy.与单一蛋白酶抑制剂疗法相比，利托那韦增强的蛋白酶抑制剂方案具有更高的病毒学疗效。
Eur J Med Res. 2003 Feb 21;8(2):56-60.
7
Simplification to coformulated elvitegravir, cobicistat, emtricitabine, and tenofovir versus continuation of ritonavir-boosted protease inhibitor with emtricitabine and tenofovir in adults with virologically suppressed HIV (STRATEGY-PI): 48 week results of a randomised, open-label, phase 3b, non-inferiority trial.在病毒学抑制的 HIV 成人患者中，与继续使用利托那韦增效蛋白酶抑制剂联合恩曲他滨和替诺福韦相比，简化的艾维雷韦/考比司他/恩曲他滨/替诺福韦与恩曲他滨和替诺福韦的联合方案（STRATEGY-PI）：一项随机、开放标签、3b 期、非劣效性试验的 48 周结果。
Lancet Infect Dis. 2014 Jul;14(7):581-9. doi: 10.1016/S1473-3099(14)70782-0. Epub 2014 Jun 5.
8
Darunavir: a review of its use in the management of HIV infection in adults.地瑞那韦：关于其在成人HIV感染管理中应用的综述
Drugs. 2009;69(4):477-503. doi: 10.2165/00003495-200969040-00007.
9
Ritonavir-boosted tipranavir demonstrates superior efficacy to ritonavir-boosted protease inhibitors in treatment-experienced HIV-infected patients: 24-week results of the RESIST-2 trial.在接受过治疗的HIV感染患者中，利托那韦增强型替拉那韦对比利托那韦增强型蛋白酶抑制剂显示出更优疗效：RESIST-2试验的24周结果
Clin Infect Dis. 2006 Nov 15;43(10):1347-56. doi: 10.1086/508352. Epub 2006 Oct 17.
10
Intracellular antiviral activity of low-dose ritonavir in boosted protease inhibitor regimens.低剂量利托那韦在增强型蛋白酶抑制剂方案中的细胞内抗病毒活性。
Antimicrob Agents Chemother. 2014 Jul;58(7):4042-7. doi: 10.1128/AAC.00104-14. Epub 2014 May 5.

引用本文的文献

1
How to use COVID-19 antiviral drugs in patients with chronic kidney disease.慢性肾脏病患者如何使用新冠抗病毒药物。
Front Pharmacol. 2023 Feb 9;14:1053814. doi: 10.3389/fphar.2023.1053814. eCollection 2023.

本文引用的文献

1
No Inhibition of MATE1/2K-Mediated Renal Creatinine Secretion Predicted With Ritonavir or Cobicistat.利托那韦或考比司他预测不会抑制 MATE1/2K 介导的肾脏肌酐分泌。
J Pharm Sci. 2019 Sep;108(9):3118-3123. doi: 10.1016/j.xphs.2019.04.023. Epub 2019 Apr 26.
2
Kidney disease in the setting of HIV infection: conclusions from a Kidney Disease: Improving Global Outcomes (KDIGO) Controversies Conference.HIV 感染相关肾脏疾病：KDIGO 争议会议的结论。
Kidney Int. 2018 Mar;93(3):545-559. doi: 10.1016/j.kint.2017.11.007. Epub 2018 Feb 3.
3
Cumulative and current exposure to potentially nephrotoxic antiretrovirals and development of chronic kidney disease in HIV-positive individuals with a normal baseline estimated glomerular filtration rate: a prospective international cohort study.
在肾小球滤过率基线正常的 HIV 阳性个体中，累积和当前暴露于潜在肾毒性抗逆转录病毒药物与慢性肾脏病的发生：一项前瞻性国际队列研究。
Lancet HIV. 2016 Jan;3(1):e23-32. doi: 10.1016/S2352-3018(15)00211-8. Epub 2015 Nov 17.
4
Clinical practice guideline for the management of chronic kidney disease in patients infected with HIV: 2014 update by the HIV Medicine Association of the Infectious Diseases Society of America.美国传染病学会艾滋病医学协会：2014年更新版《HIV感染患者慢性肾脏病管理临床实践指南》
Clin Infect Dis. 2014 Nov 1;59(9):e96-138. doi: 10.1093/cid/ciu617. Epub 2014 Sep 17.
5
Contribution of the organic anion transporter OAT2 to the renal active tubular secretion of creatinine and mechanism for serum creatinine elevations caused by cobicistat.有机阴离子转运体OAT2对肌酐肾主动肾小管分泌的作用及考比司他导致血清肌酐升高的机制
Kidney Int. 2014 Aug;86(2):350-7. doi: 10.1038/ki.2014.66. Epub 2014 Mar 19.
6
Use of glomerular filtration rate estimating equations for drug dosing in HIV-positive patients.肾小球滤过率估算方程在HIV阳性患者药物剂量计算中的应用。
Antivir Ther. 2013;18(6):793-802. doi: 10.3851/IMP2676. Epub 2013 Aug 20.
7
Performance of creatinine and cystatin C GFR estimating equations in an HIV-positive population on antiretrovirals.在接受抗逆转录病毒治疗的 HIV 阳性人群中，肌酐和胱抑素 C GFR 估算方程的表现。
J Acquir Immune Defic Syndr. 2012 Nov 1;61(3):302-9. doi: 10.1097/QAI.0b013e31826a6c4f.
8
Effect of cobicistat on glomerular filtration rate in subjects with normal and impaired renal function.考比司他对肾功能正常和受损受试者肾小球滤过率的影响。
J Acquir Immune Defic Syndr. 2012 Sep 1;61(1):32-40. doi: 10.1097/QAI.0b013e3182645648.
9
Estimated glomerular filtration rate, chronic kidney disease and antiretroviral drug use in HIV-positive patients.估算肾小球滤过率、慢性肾脏病与 HIV 阳性患者的抗反转录病毒药物使用。
AIDS. 2010 Jul 17;24(11):1667-78. doi: 10.1097/QAD.0b013e328339fe53.